KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.

Marla C Dubinsky, María Chaparro, Peter M Irving, Peter Hur, Sarah Sidhu, John C Woolcott, Wenjin Wang, Martina Goetsch, Joana Torres, Remo Panaccione

Inflamm Bowel Dis 32(6) 1075-1085

PMID41655066
PMCIDPMC13233136
DOI10.1093/ibd/izaf333
发表日期2026-02-08
入排依据:未发现恶性肿瘤人群证据。
已检查 6 张 PubMed Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;另有 1 张未列出。
摘要

摘要

INTRODUCTION: Rapid symptom relief is an important consideration for patients with ulcerative colitis (UC) experiencing a flare. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. We evaluated patient-reported symptomatic improvement from patients in the ELEVATE UC program. METHODS: This study was a post-hoc analysis of pooled daily e-diary data from patients with moderately to severely active UC receiving etrasimod or placebo in the phase III ELEVATE UC 52 and ELEVATE UC 12 trials. During the 12-week induction periods, patients self-reported stool frequency and rectal bleeding on days 1-28. Daily symptomatic response and symptomatic remission were calculated (partial modified Mayo Score). RESULTS: Overall, 787 patients (527 receiving etrasimod, 260 placebo) were included in the analysis. Etrasimod-treated patients had statistically significantly higher rates of symptomatic response and symptomatic remission during the first 28 days of therapy, with adjusted differences (95% CIs) reaching statistical significance from day 2 (5.6% [0.8-10.3], P = .022) to day 11 (4.7% [0.4-9.0], P = .034), respectively. In patients naïve to biologic/Janus kinase inhibitor therapy, symptomatic response was statistically significantly improved with etrasimod vs placebo from day 3 (8.9% [2.3-15.5], P = .008). Symptomatic improvement rates were similar with and without concomitant corticosteroid use. CONCLUSIONS: In this post-hoc analysis, improvements in UC symptoms occurred in patients receiving etrasimod vs placebo from as early as day 2. These findings indicate a rapid onset of symptomatic effect with etrasimod treatment for moderately to severely active UC. CLINICALTRIALS.GOV NUMBERS: NCT03945188, NCT03996369.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical AbstractGraphical Abstract
非 KM Figure
Figure 1Figure 1 Daily symptomatic response (A) and remission (B) with etrasimod vs placebo. Symptomatic response was defined as ≥30% decrease from baseline in pMMS (SFS plus RBS). Symptomatic remission was defined as SFS = 0 (or SFS = 1 with ≥1-point improvement from baseline) plus RBS = 0. a Day of first statistically significant adjusted difference between treatment groups. * P < .05, ** P ≤ .01, *** P ≤ .001 etrasimod vs placebo. pMMS, partial modified Mayo score; RBS, rectal bleeding subscore; SFS, stool frequency subscore; Δ, adjusted difference.
非 KM Figure
Figure 2Figure 2 Daily stool frequency response (A) and normalization (B) with etrasimod vs placebo. Stool frequency response was defined as SFS = 0 or ≥1 point improvement from baseline. Stool frequency normalization was defined as SFS = 0. a Day of first statistically significant adjusted difference between treatment groups. * P < . 05, ** P ≤ .01, *** P ≤ .001 etrasimod vs placebo. SFS, stool frequency subscore; Δ, adjusted difference.
非 KM Figure
Figure 3Figure 3 Daily rectal bleeding response (A) and remission (B) with etrasimod vs placebo. Rectal bleeding response was defined as ≥1-point improvement in RBS from baseline. Rectal bleeding remission was defined as RBS = 0. a Day of first statistically significant adjusted difference between treatment groups. * P < . 05, ** P ≤ .01, *** P ≤ .001 etrasimod vs placebo. RBS, rectal bleeding subscore; Δ, adjusted difference.
非 KM Figure
Figure 4Figure 4 Symptomatic response (A) and remission (B) by prior exposure to biologic/JAKi therapy. Symptomatic response was defined as ≥30% decrease from baseline in pMMS (SFS plus RBS). Symptomatic remission was defined as SFS = 0 (or SFS = 1 with ≥1-point improvement from baseline) plus RBS = 0. a Day of first statistically significant adjusted difference between treatment groups among patients naïve to biologic/JAKi therapy. b Day of first statistically significant adjusted difference between treatment groups among patients previously exposed to biologic/JAKi therapy. * P < . 05, ** P ≤ .01, *** P ≤ .001 etrasimod vs placebo. JAKi, Janus kinase inhibitor; pMMS, partial modified Mayo score; RBS, rectal bleeding subscore; SFS, stool frequency subscore; Δ, adjusted difference.
非 KM Figure
Figure 5Figure 5 Symptomatic response (A) and remission (B) by concomitant corticosteroid use. Symptomatic response was defined as ≥30% decrease from baseline in pMMS (SFS plus RBS). Symptomatic remission was defined as SFS = 0 (or SFS = 1 with ≥1-point improvement from baseline) plus RBS = 0. Patients in the “with corticosteroid” group received stable doses of concomitant oral corticosteroids for UC during the 12-week induction period. a Day of first statistically significant adjusted difference between treatment groups among patients not receiving concomitant corticosteroids. b Day of first statistically significant adjusted difference between treatment groups among patients receiving concomitant corticosteroids. * P < . 05, ** P ≤ .01, *** P ≤ .001 etrasimod vs placebo. pMMS, partial modified Mayo score; RBS, rectal bleeding subscore; SFS, stool frequency subscore; UC, ulcerative colitis; Δ, adjusted difference.
非 KM Figure